UC Davis Health Trial Shows Promise for Rare Liver Disease Treatment

UC Davis Health has announced promising results from a new multicenter trial for Primary Sclerosing Cholangitis (PSC), a rare liver disease. The investigational drug nebokitug demonstrated safety and potential efficacy, offering hope where no effective treatments currently exist. The findings lay the groundwork for a pivotal Phase 3 study.

• New UC Davis Health trial shows promising results for Primary Sclerosing Cholangitis (PSC).
• Investigational drug nebokitug proved safe with potential efficacy for rare liver disease.
• PSC currently lacks effective treatments apart from liver transplantation.
• Results published in the American Journal of Gastroenterology.
• This Phase 2 trial sets the stage for a crucial Phase 3 study and potential FDA approval.
• Dr. Christopher Bowlus, UC Davis Health, co-authored the significant publication.

Read the full story on Quick Digest.